大肠癌病人血清胃泌素水平变化的临床研究

（目的）探讨血清胃泌素与大肠癌的关系及其临床意义。（方法）用放免法测定39例行根治术的大肠癌病人空腹血清胃泌素水平。（结果）大肠癌病人血清胃泌素水平明显高于对照组（P＜0.05）；高分化腺癌组术前血清胃泌素水平显著高于对照组及中、低分化腺癌组（P＜0.05），术后其鲁沙素水平明显下降（P＜0．05）；Dukes’A、B期术前血清胃泌素水平明显高于对照组及Dukes’C期组（P＜0．05），Dukes’A期病人根治术后其胃沙素水平较术前明显下降（P＜0．05）。（结论）血清胃泌素可能对大肠癌细胞有内分泌促生长作用；血清胃泌素水平测定可作为大肠癌诊断及预后判断的辅助指标，并可为选择大肠癌病人行激素治疗提供参考依据。     

骨嗜酸性肉芽肿临床病理分析

作者回顾性分析２６例骨嗜酸性肉芽肿的病理肉眼镜了改变，着重探讨其组织病理特点，指出本病性质属良性非肿瘤性病变，认为骨嗜酸性肉芽肿的病理分期有利于病理诊断及指导临床治疗，并提出病理活检在该病的诊断中有重要意义。     

芩栀胶囊的一般药理作用研究

目的：观察芩栀胶囊对小鼠、大鼠精神神经系统和麻醉犬心血管系统、呼吸系统的影响，探讨其用药安全性。方法：芩栀胶囊灌胃给药，观察给药后小鼠和大鼠的一般行为表现及平衡爬杆实验，考察其对精神神经系统的影响；芩栀胶囊十二指肠给药，在八道生理记录仪上记录给药前后相关指标的变化，考察其对心血管系统及呼吸系统的影响。结果：芩栀胶囊不影响小鼠和大鼠的一般行为表现，姿势、步态正常，无肌颤、流涎、瞳孔异常等变化，在平衡爬杆时间点，大鼠30min内跌落次数〈3次；对麻醉犬呼吸频率、血压、心率等未见影响。结论：一般药理作用研究表明，芩栀胶囊对动物精神神经系统、心血管系统及呼吸系统无明显影响，提示其不良反应小。     

中药复方治疗糖尿病肾病的临床研究

目的研究中药复方治疗糖尿病肾病的疗效及作用机理.方法选非胰岛素依赖型糖尿病(NIDDM),尿蛋白排泄率(UAER):20～200μg/min123例,分3组进行治疗,疗程8周.观察治疗前后空腹血糖、UAER、血压、内皮素含量等.结果治疗后中药组空腹血糖、血压、UAER、血浆TXB2及内皮素含量显著下降,与西药对照组比较无显著差别.结论该中药复方能保护早期糖尿病肾病患者肾功能,其作用可能与改善血管内皮功能有关.     

银杏叶提取物EGb761通过caspase-3抑制TNF-α诱导HeLa细胞凋亡

目的探讨caspase-3的活化在银杏叶提取物EGb761对肿瘤坏死因子-α(TNF-α)诱导HeLa细胞凋亡中的影响.方法采用流式细胞术检测细胞凋亡,Western blot检测caspase-3 p20活性片段,Caspase-3 Colorimetric Assay试剂盒测定caspase-3活性.结果流式细胞术分析结果显示,EGb761在10～40 mg/L终浓度范围内对重组人肿瘤坏死因子-α(rhTNF-α)诱导的HeLa细胞凋亡均有显著的抑制作用(P＜0.01),呈剂量依赖关系;Western blot检测显示,rhTNF-α诱导的HeLa细胞caspase-3 p20活性片段水平增高,能被不同剂量EGb761(10～40 mg/L)明显抑制,且随EGb761浓度增加抑制效果增强;caspase-3活性测定结果显示,EGb761对rhTNF-α诱导的caspase-3活化有显著的抑制作用,且随剂量增加抑制作用增强.结论结果提示,EGb761抑制TNF-α诱导的HeLa细胞凋亡可能与其抑制caspase-3活化有关.     

卡维地洛治疗慢性心力衰竭的疗效观察

目的 :探讨卡维地洛治疗慢性心力衰竭的疗效和安全性。方法 :46例慢性心力衰竭患者随机分为治疗组 (26例)和对照组(20例)。对照组采用心力衰竭的标准治疗方案 ;治疗组在心力衰竭标准治疗方案基础上加用卡维地洛 ,治疗6mo。结果 :治疗组左室舒张末径减小 ,左室射血分数明显增加 ,与对照组比较有显著性差异 (P<0 05)。卡维地洛不良反应主要为头昏、乏力、心动过缓和低血压 ,未引起肝、肾功能损害及血象、血脂、电解质和糖代谢变化。结论 :卡维地洛治疗慢性心力衰竭有效、安全 ,能干预左室重塑。     

艾滋病合并马尔尼菲青霉病江西首例报告

目的 分析艾滋病并发马尔尼菲青霉病的发病情况、临床特征、诊断要点。方法 对艾滋病合并马尔尼菲青霉病患者的临床资料进行总结。结果 艾滋病并发马尔尼菲青霉病的患者临床症状呈现多样性，但以马尔尼菲青霉病的表现为主。结论 艾滋病且易并发马尔尼菲青霉病，应引起临床高度重视。     

湿球黑球温度指数测试和贯彻《高温作业分级标准》中的几个问题探讨

我国幅员广阔，各地的气候差异很大，只用温差一个参数很难准确地反映高温作业的实际情况。湿球黑球温度（WBGT）指数是由黑球、自然湿球、干球3个温度综合构成的。它综合考虑了空气温度、风速、空气湿度和辐射热（平均辐射温度）4个因素，可以比较准确地反映工作地点的气象条件。1997年正式颁布的《高温作业分级标准》（GB／T4200-1997）采用了WBGT指数来评价高温车间的气象条件。由于对标准的内容和仪器的性能理解上的一些问题，在贯彻标准和应用仪器测试WBGT指数时，也还存在一些问题。     

Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.

Bortezomib [N-(2,3-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid] is a potent first-in-class dipeptidyl boronic acid proteasome inhibitor that was approved in May 2003 in the United States for the treatment of patients with relapsed multiple myeloma where the disease is refractory to conventional lines of therapy. Bortezomib binds the proteasome via the boronic acid moiety, and therefore, the presence of this moiety is necessary to achieve proteasome inhibition. Metabolites in plasma obtained from patients receiving a single intravenous dose of bortezomib were identified and characterized by liquid chromatography/mass spectrometry (LC/MS) and liquid chromatography/tandem mass spectrometry (LC/MS/MS). Metabolite standards that were synthesized and characterized by LC/MS/MS and high field nuclear magnetic resonance spectroscopy (NMR) were used to confirm metabolite structures. The principal biotransformation pathway observed was oxidative deboronation, most notably to a pair of diastereomeric carbinolamide metabolites. Further metabolism of the leucine and phenylalanine moieties produced tertiary hydroxylated metabolites and a metabolite hydroxylated at the benzylic position, respectively. Conversion of the carbinolamides to the corresponding amide and carboxylic acid was also observed. Human liver microsomes adequately modeled the in vivo metabolism of bortezomib, as the principal circulating metabolites were observed in vitro. Using cDNA-expressed cytochrome P450 isoenzymes, it was determined that several isoforms contributed to the metabolism of bortezomib, including CYP3A4, CYP2C19, CYP1A2, CYP2D6, and CYP2C9. The development of bortezomib has provided an opportunity to describe the metabolism of a novel boronic acid pharmacophore.     

Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations

Low molecular weight heparin (LMWH) is commonly used to prevent postoperative thromboembolism. Currently, there is no convenient test to measure the degree of anticoagulation from LMWH. This prospective study examines the relationship of thromboelastography and serum anti-Xa concentration in patients treated with enoxaparin. Twenty-four adult patients scheduled for orthopedic surgery using epidural anesthesia were enrolled. Epidural catheters were removed the morning after surgery before the commencement of subcutaneous enoxaparin 30 mg twice daily. Venous blood samples were obtained at 1) the induction of anesthesia (baseline), 2) immediately before the third dose of enoxaparin postoperatively (Day 2-trough), 3) 4 h after the third dose postoperatively (Day 2-peak), and 4) immediately before the fifth dose postoperatively (Day 3-trough). Whole blood samples were obtained for thromboelastography, activated clotting time, and anti-Xa level analyses at each of the four time intervals. At the four sample intervals, the r time (mean +/- SEM). (20 +/- 1, 25 +/- 2, 51 +/- 6, 31 +/- 3 mm) and the k time (9 +/- 0. 7, 12 +/- 1, 27 +/- 5, 14 +/- 2 mm) of the thromboelastograph were significantly correlated with the expected peak and trough levels of LMWH and serum anti-Xa levels (P: < 0.05). At the Day 3-trough, thromboelastograph r times exceeded the normal range in 6 of 25 patients (25%). Prolongation of r time and k time on postoperative Day 3 may indicate an exaggerated response to LMWH. Thromboelastography is a test that could potentially correlate with the degree of anticoagulation produced by low molecular weight heparin. Implications: Thromboelastography is a test that could potentially correlate with the degree of anticoagulation produced by low molecular weight heparin. The r time from the thromboelastogram correlates with serum anti-Xa concentration.